CIK 0001515673
- Large accelerated filer
Ultragenyx Pharmaceutical Inc.
Sign in to watch- Ticker
- RARE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 272546083
- Phone
- +1 415-483-8800
- Business address
- 60 LEVERONI COURT, NOVATO, CA, 94949
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $127,561
- in 3 filings, $17K under 10b5-1 plans
Net −$127,561. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-10-12 | Dier Mardi CFO & Executive Vice President | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2020-10-08 | Parschauer Karah Herdman EVP and General Counsel | Exercise or conversion | +10,000 | $54.50 | $545K | 34,293 |
| 2020-10-08 | Parschauer Karah Herdman EVP and General Counsel | Sale | −10,000 | $95.00 | $950K | 24,293 |
| 2020-10-08 | Parschauer Karah Herdman EVP and General Counsel | Exercise or conversion · Stock Option (Right to Buy) | −10,000 | 35,000 | ||
| 2020-10-06 | Parschauer Karah Herdman EVP and General Counsel | Exercise or conversion | +10,000 | $48.43 | $484K | 34,293 |
| 2020-10-06 | Parschauer Karah Herdman EVP and General Counsel | Sale | −10,000 | $90.00 | $900K | 24,293 |
| 2020-10-06 | Parschauer Karah Herdman EVP and General Counsel | Exercise or conversion · Stock Option (Right to Buy) | −10,000 | 17,000 | ||
| 2020-09-23 | Parschauer Karah Herdman EVP and General Counsel | Exercise or conversion | +10,000 | $48.43 | $484K | 34,293 |
| 2020-09-23 | Parschauer Karah Herdman EVP and General Counsel | Sale | −10,000 | $85.00 | $850K | 24,293 |
| 2020-09-23 | Parschauer Karah Herdman EVP and General Counsel | Exercise or conversion · Stock Option (Right to Buy) | −10,000 | 27,000 | ||
| 2020-09-01 | KAKKIS EMIL D President & CEO | Sale | −30,000 | $82.63 | $2.5M | 2,389,741 |
| 2020-08-21 | Aliski William Director | Exercise or conversion | +5,000 | $58.74 | $294K | 62,018 |
| 2020-08-21 | Aliski William Director | Sale | −5,000 | $86.57 | $433K | 57,018 |
| 2020-08-21 | Aliski William Director | Exercise or conversion · Stock Option (Right to Buy) | −5,000 | 0 | ||
| 2020-08-17 | Parschauer Karah Herdman EVP and General Counsel | Exercise or conversion | +10,000 | $54.50 | $545K | 36,663 |
| 2020-08-17 | Parschauer Karah Herdman EVP and General Counsel | Sale | −10,000 | $88.44 | $884K | 26,663 |
| 2020-08-17 | Parschauer Karah Herdman EVP and General Counsel | Sale | −2,370 | $88.39 | $209K | 24,293 |
| 2020-08-17 | Parschauer Karah Herdman EVP and General Counsel | Exercise or conversion · Stock Option (Right to Buy) | −10,000 | 45,000 | ||
| 2020-08-17 | Sharp Shalini CFO & Executive Vice President | Sale | −461 | $88.24 | $41K | 100,747 |
| 2020-08-17 | Sharp Shalini CFO & Executive Vice President | Sale | −2,560 | $88.54 | $227K | 98,187 |
Page 24 of 32 · 632 trades